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In humans, heterozygous mutations in the adenosine
triphosphate-dependent chromatin remodeling gene CHD7 cause
CHARGE syndrome, a common cause of deaf–blindness, balance
disorders, congenital heart malformations, and olfactory dysfunction with
an estimated incidence of approximately 1 in 10,000 newborns. The
clinical features of CHARGE in humans and mice are highly variable and
incompletely penetrant, and most mutations appear to result in
haploinsufficiency of functional CHD7 protein. Mice with heterozygous
loss of function mutations in Chd7 are a good model for CHARGE
syndrome, and analyses of mouse mutant phenotypes have begun to clarify
a role for CHD7 during development and into adulthood. Chd7
heterozygous mutant mice have postnatal delayed growth, inner ear
malformations, anosmia/hyposmia, and craniofacial defects, and Chd7
homozygous mutants are embryonic lethal. A central question in
developmental biology is how chromodomain proteins like CHD7 regulate
important developmental processes, and whether they directly activate or
repress downstream gene transcription or act more globally to alter
chromatin structure and/or function. CHD7 is expressed in a wide variety
of tissues during development, suggesting that it has tissue-specific and
developmental stage-specific roles. Here, we review recent and ongoing
analyses of CHD7 function in mouse models and cell-based systems.
These studies explore tissue-specific effects of CHD7 deficiency, known
CHD7 interacting proteins, and downstream target sites for CHD7 binding.
CHD7 is emerging as a critical regulator of important developmental
processes in organs affected by human CHARGE syndrome.
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Regulation of eukaryotic genes is essential for
normal tissue and organ development and main-
tenance. Chromatin structure has a vital role in
gene regulation, via its effects on cellular pro-
liferation and maintenance of the differentiated
state. A central goal in current developmental biol-
ogy is to identify molecular pathways that reg-
ulate chromatin structure and gene expression,
and to understand how this regulation influences
organogenesis. In humans, haploinsufficiency for
the chromodomain helicase DNA-binding gene
7 (CHD7 ) causes CHARGE syndrome, a mul-
tiple anomaly condition characterized by ocular
coloboma, heart defects, atresia of the choanae,
retarded growth and development, genital hypopla-
sia, and ear abnormalities including deafness
and vestibular disorders (1). The identification
of CHD7 as the causative gene for CHARGE
syndrome has led to several recent advancements
in our understanding of this complex disorder.
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Furthermore, with the establishment of mouse
models for CHARGE, it is now possible to begin
detailed molecular analyses of how CHD7 func-
tions in specific tissues and cell types both during
development and into adulthood. Here, we review
recent studies which explore the underlying molec-
ular genetic mechanisms by which CHD7 regulates
the development and maintenance of various tis-
sues. Researchers are now poised to charge into the
future with a well-equipped toolbox for analyzing
CHD7 function.
CHD7 mutations cause CHARGE syndrome
In humans, heterozygous CHD7 mutations cause
CHARGE syndrome, a clinically variable, multi-
ple congenital anomaly condition affecting devel-
opment of the inner ear, central nervous sys-
tem (CNS), olfactory system, eyes, heart, choanae
(the region between the oropharynx and nasal
passages), genitalia, and craniofacial structures
including the hard and soft palates, lip, external
ear, and midface (2–6). CHARGE is a common
cause of deaf–blindness, balance disorders, olfac-
tory dysfunction, and congenital heart malforma-
tions, with an estimated incidence of 1:10,000 in
newborns (7–9). The human CHD7 gene spans
188 kb on chromosome 8q12.1, with a 8994 bp
open reading frame and translation start site
in exon 2. Heterozygosity for nonsense, dele-
tion, or missense CHD7 mutations occurs in
60–80% of patients with CHARGE (2–5, 10, 11).
Human CHD7 mutations are distributed through-
out the coding sequence and do not appear
to be correlated with specific aspects of the
clinical phenotype (2–5, 10, 11). Most human
CHD7 mutations identified thus far are de novo;
however, evidence for germline mosaicism has
been reported in families with multiple affected
siblings (3, 12–14).
The clinical features of CHARGE in humans
and mice are highly variable and incompletely pen-
etrant. We recently reviewed all reports of CHD7 -
mutation positive CHARGE individuals, and found
that the most commonly affected organ in humans
with CHD7 mutations is the ear (2–6, 12–35). Ear
defects in CHARGE include temporal bone abnor-
malities, external ear malformations, and hearing
loss (2–6, 12–35). In addition to ear abnormal-
ities, a majority of CHARGE patients are also
affected by some combination of the following:
ocular coloboma, heart defects, delayed growth
and development, and genital hypoplasia (2–6,
12–35). Although olfactory function is less com-
monly analyzed in CHARGE patients, a majority
of CHARGE patients analyzed have some form of
olfactory defect including olfactory bulb hypopla-
sia and/or aplasia, and impaired olfaction rang-
ing from mild hyposmia to anosmia (16, 24, 26,
28, 36–40). Less commonly reported clinical fea-
tures associated with CHARGE and CHD7 muta-
tions include choanal atresia, facial nerve palsy,
cleft lip and/or plate, and tracheoesophageal fis-
tula (2–6, 12–35). The variability in CHARGE
features suggests that mutations in CHD7 lead
to pleiotropic developmental defects; however, the
mechanisms underlying these defects have not yet
been determined.
Mouse models of CHARGE and tissue-specific
defects
Mouse CHD7 protein is comprised of 2985 amino
acids, and has a predicted molecular weight of
334 kDa. Both human and mouse Chd7 genes
contain 38 exons, and have similar exon–intron
structures. At the protein level, there is 94.7%
sequence identity between mouse and human
CHD7, which corresponds to 89.7% nucleotide
sequence identity. Heterozygous Chd7 mutant
mice were originally identified by ethylnitrosourea
(ENU) mutagenesis, with each of nine differ-
ent lines carrying a single nonsense Chd7 muta-
tion (41). These nine Chd7 mutant mouse lines
are viable, with phenotypes that include head bob-
bing, circling behaviors, disrupted lateral semi-
circular canals, hyperactivity, reduced postnatal
growth, variable cleft palate, choanal atresia, car-
diac septal defects, hemorrhage, prenatal death,
genital abnormalities, keratoconjunctivitis sicca
(dry eye), and olfactory defects (41). Our lab-
oratory generated heterozygous loss of function
Chd7 Gt/+ mice using Chd7 gene trap embryonic
stem (ES) cells (42). Chd7 Gt/+ mice have pheno-
typic features similar to those generated by ENU
mutagenesis (42). Chd7 Gt/Gt mice are embryonic
lethal by E11, and exhibit developmental growth
delays such as reduction in size of multiple organs
including brain, eyes, ears, and craniofacial struc-
tures (42). The intrauterine lethality of homozy-
gous Chd7 Gt/Gt embryos and the severity of
developmental malformations in Chd7 Gt/+ mice
indicate a lack of redundancy for prenatal Chd7
function in the mouse genome and suggest impor-
tant roles for CHD7 in organogenesis (42). Chd7
is expressed in specific tissues during mouse and
human embryogenesis including the ear, brain, cra-
nial nerves, olfactory epithelium, olfactory bulb,
pituitary, heart, liver, eye, gut, kidney, and cran-
iofacial structures (Fig. 1) (5, 39, 41, 42). Chd7
is also expressed in the adult mouse olfactory
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Fig. 1. Chd7 is expressed in CHARGE-related tissues during
development. Frozen sections from E14.5 Chd7 Gt/+ embryos
show β-galactosidase (X-gal staining) in CHARGE-related
organs including (a) olfactory bulbs (ob), (b) olfactory epithe-
lium (oe), (c) limb, (d) heart (hrt), (e) kidney (kid), (f) enteric
neurons of the gut (en), (g) crista (ca) and cochlea (coc) of
the inner ear, and (h) lens (le) and retina (re) of the eye. All
sections are in the coronal orientation.
epithelium, olfactory bulb, and in the rostral migra-
tory stream (39).
Inner ear abnormalities in humans and mice
with CHD7 deficiency
The most consistent clinical feature associated with
CHARGE syndrome is inner ear defects, including
semicircular canal dysplasia that typically affects
all three canals, and a Mondini form of cochlear
hypoplasia (35, 43–45). In addition, both facial
and vestibulocochlear nerve abnormalities are also
reported (44, 46). Cochlear implants are a success-
ful treatment for some CHARGE patients, pro-
vided there are no underlying nerve abnormali-
ties. CHARGE patients also display vestibular dys-
function, including delayed postural development,
abnormal vestibular testing, and balance/motor
problems (47, 48). Although absence of the semi-
circular canals is believed to be a major cause of
balance dysfunction, other factors such as ocular
malformations, CNS defects, and skeletal abnor-
malities are also likely contributors.
Heterozygous Chd7 mice display circling and
head-bobbing behaviors consistent with vestibular
dysfunction phenotypes (41, 42). Detailed exam-
ination of Chd7 mutant mouse ears indicates a
variety of lateral semicircular canal malformations,
smaller posterior semicircular canals, and defects
in innervation of the posterior crista (Fig. 2) (42,
49–52).
During embryonic development, semicircular
canals are formed by sequential outpocketing,
fusion of the otic epithelium, and tightly controlled
processes to form three canals (53). Semicircu-
lar canal dysgenesis can be caused by mutations
in a variety of transcription factors and signaling
molecules (Table 1). Semicircular canal abnormal-
ities observed in Chd7 mutant mice are postu-
lated to be the result of smaller posterior and lat-
eral canal outpocketings and delayed fusion of the
epithelium (Fig. 2) (51). Perturbations in signaling
cascades both within the inner ear epithelium and
surrounding mesenchyme can also result in semi-
circular canal defects (Table 1) (54). In summary,
the inner ear phenotypes observed in heterozy-
gous Chd7 mice are similar to those reported in
CHARGE patients and include semicircular canal
defects, innervation defects, and vestibular dys-
function. The precise molecular mechanisms of
Chd7 function within the ear are still not under-
stood, but probably involve complex interactions
with essential transcription factors expressed dur-
ing ear development.
Impaired olfaction in humans and mice with
CHD7 deficiency
Genital hypoplasia, delayed puberty, and delayed
growth are common in CHARGE individuals (16,
24, 26, 28, 40). These features often occur
in conjunction with olfactory defects, includ-
ing hypoplastic olfactory bulbs and reduced
olfaction (16, 24, 26, 28, 40). Previous studies
of endocrine dysfunction in CHARGE patients
reported growth delays, but only 9% of CHARGE
patients had growth hormone deficiency, and
growth delay was not associated with thyroid-
stimulating hormone or adrenocorticotropic hor-
mone deficiency (40). Analysis of female
CHARGE patients over the age of 12 showed
lack of spontaneous puberty and no response
to stimulation with gonadotropin-releasing hor-
mone (GnRH) (40). A majority of male CHARGE
patients had low testosterone levels and cryp-
torchidism and/or micropenis. In contrast to
females, male response to GnRH stimulation
was variable and did not always correlate with
testosterone levels (40). Endocrine dysfunction in
CHARGE individuals is therefore likely to be mul-
tifactorial, with variable influence on olfaction,
somatic growth, puberty, and fertility.
Mutations in CHD7 have been reported in indi-
viduals with Kallmann syndrome with and with-
out a CHARGE syndrome diagnosis (24, 26).
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Table 1. Mouse models of human semicircular canal dysgenesis
Gene Type of protein Mouse inner ear defects Human inner ear defects References
Brn4 (Pou3f4) Pou-domain
transcription factor
ASC abnormalities X-linked hereditary deafness type 3:





LSC, PSC, and associated
crista abnormalities
CHARGE syndrome: outer and inner ear
abnormalities including semicircular
canal defects and deafness
41, 42, 49
Eya1 Transcription factor ASC, PSC, LSC, and
associated crista absent
Branchio-oto-renal syndrome: outer,
middle, and inner ear abnormalities and
deafness
71, 72
Fgf3 Fibroblast growth factor ASC, PSC, and LSC
abnormalities
Syndromic deafness: inner ear agenesis
and deafness
73–75
Fgf10 Fibroblast growth factor ASC, PSC, LSC, and
associated crista
abnormalities
LADD syndrome: outer ear abnormalities,
inner ear abnormalities, and deafness
76, 77
Jag1 Notch receptor ligand ASC, PSC, and LSC
abnormalities
Alagille syndrome: posterior semicircular
canal defects
51, 78
Six1 Transcription factor ASC, PSC, and LSC absent Branchio-oto-renal syndrome: outer,
middle, and inner ear abnormalities and
deafness
79–81
ASC, anterior/superior semicircular canal; LSC, lateral semicircular canal; PSC, posterior semicircular canal.
Fig. 2. Model of inner ear development in wild type and Chd7 heterozygous mutant mice. The E11.5 otocyst extends dorsally
to form the endolymphatic duct (ed, gray) and ventrally to form the cochlea (coc), and neuroblasts delaminate from the ventral
epithelium to occupy the statoacoustic ganglion (sag, shown in blue). By E12.5, the epithelium of the canal pouches fuses to form the
anterior (asc), posterior (psc), and lateral (lsc) semicircular canals. Between E13.5 and adulthood, the vestibular apparatus continues
to mature, the cochlea completes its coiling, and the sensory epithelium becomes completely innervated. In Chd7 heterozygous
mutant ears, the lateral and posterior semicircular canals are truncated (lt), small, or misshapen. In addition, the nerve to the
posterior ampulla (npa) is disrupted. Normal developmental structures are shown by a dashed line in Chd7 heterozygous mutants.
Kallmann syndrome is primarily characterized by
idiopathic hypogonadotropic hypogonadism and
anosmia (26, 55, 56). Idiopathic hypogonadotropic
hypogonadism is characterized by impaired or
absent sexual development because of sex steroid
hormone deficiency, with low serum levels of the
pituitary gonadotropins follicle-stimulating hor-
mone (FSH) and luteinizing hormone (LH) as
14
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well as infertility (26, 55, 56). Kallmann-like fea-
tures in humans are often associated with impair-
ment of embryonic GnRH neuronal migration
along olfactory neuronal tracts from the olfactory
placode to the hypothalamus (26, 55, 56). Kall-
mann syndrome is genetically heterogeneous, with
mutations reported in a variety of genes includ-
ing KAL1, FGFR1, FGF8, PROKR2, PROK2,
and CHD7 (26, 55–59). Mouse models exist for
several of the genes associated with Kallmann
syndrome (hypogonadotropic hypogonadism and
reduced olfaction) and are listed in Table 2.
Odorant detection is a complex process that
requires normal function of several different tis-
sues and organs. Odorants are first detected in the
nasal olfactory epithelium by odorants binding to
specific odorant receptors located on the surface
of olfactory cilia (Fig. 3). Bound odorants acti-
vate olfactory sensory neurons, which are bipolar
neurons that project axons to the glomeruli in the
olfactory bulb. Olfactory bulb glomeruli contain
dendrites of mitral cells and a variety of interneu-
rons and periglomerular cells. Neuronal signals are
then relayed to higher brain regions in the CNS.
Table 2. Mouse models of human Kallmann syndrome
(idiopathic hypogonadotropic hypogonadism and olfactory
dysfunction)




Fgf8 Fibroblast growth factor 57, 82, 83
Fgfr1 Fibroblast growth factor
receptor
57
Prok2 (Pk2) Prokineticin 84, 85
Prokr2 (Pkr2) Prokineticin receptor 86
As olfactory ability is reliant upon a number
of components working in a coordinated fashion,
we chose to look at olfactory function in mice
utilizing methods that are not influenced by behav-
ioral issues such as circling and hyperactivity. We
observed, using electro-olfactogram of the olfac-
tory epithelium, a lack of functional responses in
olfactory sensory neurons to a variety of odorants
in young (6-week old) adult Chd7 Gt/+ mice (39).
Additionally, we found that young adult Chd7 Gt/+
mice have fewer olfactory sensory neurons and
Fig. 3. Model of olfactory function in wild type and Chd7 Gt/+ mice. Following inhalation, odorants are detected in the olfactory
epithelium by binding to specific odorant receptors located on the surface of olfactory cilia. Bound odorants activate olfactory
sensory neurons, which are bipolar neurons that project axons to the glomeruli in the olfactory bulb. Each olfactory sensory neuron
(e.g. blue, red, green, and purple) contains one type of odorant receptor in the cilia, and each neuron with that type of odorant
receptor projects an axon to the same glomerulus in the olfactory bulb. Electrical signals sent by olfactory sensory neurons are
detected by mitral cell dendrites in the glomeruli. These signals are then sent to higher brain regions in the central nervous system.
Wild type mouse olfactory epithelium contains densely packed olfactory sensory neurons which project to the olfactory bulb.
However, Chd7 Gt/+ young adult mice have 30% fewer olfactory sensory neurons and olfactory bulb hypoplasia. We hypothesize
that aged Chd7 Gt/+ mice have a greater reduction in both olfactory sensory neurons and size of the olfactory bulb.
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Fig. 4. The chromodomain family of proteins contains nine members that are subdivided into three classes on the basis of shared
protein motifs. CHD7 is a member of the third class together with CHD5, CHD6, CHD8, and CHD9.
olfactory bulb hypoplasia (Fig. 3) (39). In order
to identify the underlying mechanisms by which
CHD7 regulates olfactory sensory neurons, we
analyzed cell type-specific expression of Chd7 in
the young adult olfactory epithelium (39). CHD7
is present in 97% of proliferating neural stem
cells and in Ascl1-positive (Mash1) and NeuroD-
positive pro-neuronal cells in the adult mouse
olfactory epithelium by immunofluorescence (39).
Chemical ablation of the adult mouse olfactory
epithelium in Chd7 Gt/+ mice results in reduced
regenerative capacity of olfactory sensory neurons,
indicating ongoing requirements for CHD7 in
adulthood (39). Consequently, we hypothesize that
with age or insult, further reductions in olfactory
sensory neurons and olfactory bulb size could
occur, but this remains to be formally tested
(Fig. 3). In a related study, Chd7 Whi/+ mice
had reduced olfaction (assayed by sniff response
to mouse urine compared with water), olfac-
tory bulb hypoplasia, reproductive dysfunction,
and decreased fertility compared with wild type
mice (60). Taken together, these studies suggest
that CHD7 has critical functions in olfactory sen-
sory neuron integrity and odorant detection.
CHD7 and other CHD proteins: classification
and characteristics
CHD proteins are a part of the large group
of adenosine triphosphate (ATP)-dependent chro-
matin remodelers. The mammalian genome en-
codes approximately 30 such genes that appear to
be non-redundant and vital for normal embryonic
development (61). Many ATP-dependent chro-
matin remodeling genes show haploinsufficiency,
indicating that their products may be involved
in rate-limiting steps during development (61).
CHD7 is one of nine ATP-dependent chromatin
remodeling CHD enzymes that are characterized
by the presence of two chromodomains, centrally
located helicase domains, and less well defined
carboxy terminal domains (Fig. 4) (61–63). CHD
proteins use ATP hydrolysis to regulate access to
DNA by altering nucleosomes (61–63). The nine
CHD proteins are broadly classified into three sub-
families based upon their amino acid sequence
and functional protein domains (61–63). CHD7
is a member of the class III chromodomain pro-
teins together with CHD5, CHD6, CHD8, and
CHD9 (61–63). CHD7 contains a SANT (SWI3,
ADA2, N-COR, and TFIIB) domain, which is con-
served among many regulators of transcription and
chromatin structure, and is believed to function as
a histone tail-binding module (64). CHD7, CHD8,
and CHD9 contain two BRK domains, the func-
tion of which appears to be specific to higher
eukaryotes as it is not present in yeast chromatin
remodeling factors (63). CHD7 and the other eight
CHD proteins are an interesting class of novel
ATP-dependent chromatin remodelers with unique
protein motifs that are incompletely characterized.
To date, CHD7 is the only member of this class of
proteins for which mutations have been associated
with a well-described human syndrome.
CHD7-binding sites and interacting proteins
Recent studies have begun to clarify a role for
CHD7 in regulating gene expression during tis-
sue development and maintenance. In a study
using chromatin immunoprecipitation followed by
microarray-based sequence analysis (ChIP-chip),
CHD7 has been shown to bind in a cell type-
specific manner to methylated histone H3 lysine
4 in enhancer regions of numerous genes in
human colorectal carcinoma cells, human neurob-
lastoma cells, and mouse ES cells before and
16
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Fig. 5. Model for CHD7 transcriptional regulation. CHD7
binds to enhancer regions of target genes together with a
tissue-specific complex of proteins. The CHD7 tissue-specific
complex either activates or represses downstream target gene
expression in a developmental stage-specific manner.
after differentiation, indicating that CHD7 may
have temporal and tissue-specific functions (65).
CHD7 has also been implicated to regulate multi-
potent neural crest-like cells by binding to PBAF
components including BRG1, BAF170, BAF155,
BAF57, PB1, ARID2, and BRD7 (66). In mes-
enchymal stem cells, CHD7 regulates cell fate
specification during osteoblast and adipocyte dif-
ferentiation (67). CHD7 forms a complex with
NLK, SETDB1, and PPAR-γ, and binds to methy-
lated lysine 4 and lysine 9 residues on histone
H3 at PPAR-γ target promoters, which suppresses
ligand-induced transactivation of PPAR-γ target
genes (67). Additionally, the CHD7 Drosophila
orthologue, Kismet, is involved in transcriptional
elongation by RNA polymerase II through recruit-
ment of ASH1 and TRX and may help main-
tain stem cell pluripotency by regulating methyla-
tion of histone H3 lysine 27 (68). Together, these
data indicate multiple roles for CHD7 in regulat-
ing transcription, potentially affecting tissue and
developmental stage-specific processes (Fig. 5).
Summary and future studies
In summary, CHARGE syndrome is a monogenic
disease which exhibits highly variable expressiv-
ity. Organs affected in CHARGE during develop-
ment include neural tube, neural crest, and placodal
derivatives. Certain tissues such as the inner ear
and olfactory system appear to be highly sensi-
tive to CHD7 dosage, whereas other organs such
as the heart, kidney, and skeletal systems are more
variably affected. CHD7 haploinsufficiency occurs
in 60–80% of CHARGE patients and mutations
in CHD7 are distributed throughout the coding
sequence. Further studies are necessary to deter-
mine whether the remaining 20–40% of CHARGE
patients have mutations in CHD7 regulatory ele-
ments or in other genes. It is also possible that
unidentified environmental factors contribute to the
phenotype. Heterozygous Chd7 mutant mice and
in vitro ES cell analyses have begun to clarify
a role for CHD7 in the development and main-
tenance of a variety of tissues (39, 41, 42, 60,
65–68). These studies suggest that CHD7 has roles
in stem cell maintenance and cell fate specifica-
tion (39, 65–68). In vitro analyses have impli-
cated that CHD7 is a member of the PBAF com-
plex in neural crest-like cells (66) and that CHD7
forms a complex with NLK, SETDB1, and PPAR-
γ (67). These studies open the door for further
in vivo assays which should identify important
downstream effectors of CHD7. Taken together,
these observations suggest that CHD7 is likely
to participate in combinatorial protein complexes
which bind DNA in enhancer regions and regulate
gene transcription in a temporal and tissue-specific
manner.
To date, much has been learned about CHARGE
syndrome, but several important questions remain
unanswered. Is there a core set of CHD7-binding
partners that regulate CHD7 function, and if so
are they tissue and age specific? What are the
upstream regulators of CHD7 ? Finally, can we
use information about CHD7 function in cells to
help design therapies for patients diagnosed with
CHARGE syndrome?
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